Answers are grounded in this paper and cite their sources.
Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despiteits clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteractit. This study investigates the cost-effectiveness of Brentuximab Vedotin (BV) in combination with cyclophosphamide,doxorubicin and prednisone (CHP) for the front-line treatment of patients with sALCL in Italy.Methods: The analysis was conducted from the perspective of the National Health Service using a three-statepartitioned survival model with cycles lasting 21 days and a lifetime time horizon. The survival curves were takenfrom three-year follow-up data of ECHELON-2 trial. Costs were obtained from published literature and nationaltariffs. For all drugs, ex-factory prices net of the mandatory reductions required by law were considered.Results: Compared with CHOP, BV in combination with CHP was associated with an increase of € 46,349 totalcosts, 2.3 life years and 1.8 quality-adjusted life-years (QALYs) respectively. The incremental cost-utility ratios(ICUR) were estimated equal to € 25,367/QALY compared with CHOP, resulting below the value of € 41,411/QALYfor severe diseases in Italy.Conclusions: Based on data from 3 years of follow-up from the ECHELON-2 trial, BV in combination with CHP isestimated a cost-effective option versus CHOP for the front-line treatment of sALCL in Italy. Data from 5-year fromthe ECHELON-2 trial confirmed the advantage in terms of PFS and OS. The analysis also suggested that treatmentwith BV+CHP may be cost-effective compared with CHOEP.
No takes yet. Share an insight, caveat, or question.
Marcellusi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: